MENLO PARK, Calif.– Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the appointment of Amirali Kia, Ph.D., as Vice President of Data Science and AI. In this position, Dr. Kia will join the leadership team and take on the responsibility for delivering best-in-class data science capabilities.
“We are delighted to welcome Amirali to our team to lead data science and AI initiatives. AI has been a cornerstone of our technology since the company’s inception, and Amirali’s expertise will play a pivotal role in steering our data science and AI initiatives to new heights. His focus will be on expanding the AI infrastructure and utilizing artificial intelligence to develop models and tools that enhance our understanding of cell morphology and cell biology,” said Mahyar Salek, Ph.D., President and CTO of Deepcell. “Through his extensive career in artificial intelligence, deep learning, and computational biology, Amirali has consistently shown his ability to build and lead high-performing data science teams, develop algorithms and tools to enhance performance of both instruments and assays, and expand IP portfolios of companies in the area of data science and AI.”
Prior to joining Deepcell, Amirali was the Vice President of AI and Computational Biology at Harbinger Health where he helped establish the AI infrastructure and apply advanced algorithms to detect early cancer signals in blood. Prior to that role, he served as the director of the Core-AI team at Illumina, where he successfully utilized AI for core Illumina technologies such as instrument analysis algorithms and protein engineering. Amirali earned his Ph.D. in High-Performance Computing and its Applications in Computational Biology from Stanford University.
“Deepcell has created a powerful platform to advance our collective understanding of cell biology with industry leading data science and AI at its core,” said Amirali Kia, Ph.D., VP of Data Science and AI. “I look forward to working with the team to drive continuous improvements in our modeling approaches as we expand the capabilities of the REM-I platform and dramatically scale the number of cells being analyzed with our Human Foundation Model.”
Deepcell is a life science company which brings artificial intelligence to cell biology, unlocking a new field of high-dimensional biological discovery known as morpholomics. Through Deepcell’s AI-powered imaging and microfluidics solution, the REM-I Platform, the company is enabling a new scale of cell biology research and single cell analysis leveraging cellular morphology for unbounded discovery. Deepcell’s platform leverages its artificial intelligence model, the Human Foundation Model, to identify and sort cells based on morphological distinctions helping power basic and translational research and offering future applications in diagnostic testing and therapeutics targeting. The company was spun out of Stanford University in 2017 and has raised nearly $100 million in venture capital. It is based in Menlo Park, California. Learn more at www.deepcell.com or follow us on LinkedIn, Twitter, and YouTube.